var data={"title":"Sodium benzoate: Pediatric drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Sodium benzoate: Pediatric drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/8151?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062157\" class=\"list_set htclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Therapeutic Category</span>\n    <ul>\n      <li>\n        <span class=\"list-set-name\">Ammonium Detoxicant</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Hyperammonemia Agent</span>;</li>\n      <li>\n        <span class=\"list-set-name\">Urea Cycle Disorder (UCD) Treatment Agent</span></li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F11445041\" class=\"block don drugH1Div\"><span class=\"drugH1\">Dosing: Neonatal</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Sodium benzoate is not commercially available as a ready-to-use product; however, some centers are still using compounded formulations when necessary. IV dosing is usually required for acute episodes; if IV administration is necessary, see the Sodium Phenylacetate and Sodium Benzoate monograph for information about a commercially available parenteral product.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urea cycle disorders, long-term therapy:</b> Very limited data available: Dosage should be individualized based on patient response; consult with metabolic specialist: Oral: 250 to 500 mg/kg/day in 3 to 4 divided doses given with feeds (H&auml;berle 2012; Kliegman 2016; Maestri 1991)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062154\" class=\"block dos drugH1Div\"><span class=\"drugH1\">Dosing: Usual</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Sodium benzoate is not commercially available as a ready-to-use product; however, some centers are still using compounded formulations when necessary. IV dosing is usually required for acute episodes; if IV administration is necessary, see the Sodium Phenylacetate and Sodium Benzoate monograph for information about a commercially available parenteral product.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>Urea cycle disorders, long-term therapy:</b> Very limited data available: Dosage should be individualized based on patient response; consult metabolic specialist: Infants, Children, and Adolescents: Oral: 250 to 500 mg/kg/day in 3 to 4 divided doses given with meals (H&auml;berle 2012; Kliegman 2016, Maestri 1991; Maestri 1996).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F247197\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;display:inline\">Powder: 454 g</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062160\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">Oral: Not commercially available; must be compounded using chemical powder; consult metabolic specialist</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062159\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:0em;display:inline\">Adjunctive therapy for the prevention and treatment of hyperammonemia due to suspected or proven urea cycle disorders</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51130873\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:0em;display:inline\">\n      <b>Note:</b> Sodium benzoate is not commercially available as a ready-to-use product; however, some centers are still using compounded formulations when necessary.</p>\n    <p style=\"text-indent:0em;margin-top:2em;\">Use with caution in patients with Reye's syndrome, propionic or methylmalonic acidemia; use with caution in neonates with hyperbilirubinemia due to potential displacement of bilirubin from albumin binding sites (Kliegman 2016).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13300050\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6222963\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=12794&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Probenecid: May increase the serum concentration of Sodium Benzoate. Specifically, probenecid may inhibit the renal transport of the hippuric acid metabolite of sodium benzoate.<i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062156\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">Plasma ammonia, plasma amino acid (quantitative) and glutamine concentrations, blood glucose, serum electrolytes, hepatic and renal function tests, blood gases, neurologic status, physical signs/symptoms of hyperammonemia (ie, lethargy, ataxia, confusion, vomiting, seizures, and memory impairment)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F247189\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Assists in lowering serum ammonia levels by activation of a nonurea cycle pathway (the benzoate-hippurate pathway); ammonia in the presence of benzoate will conjugate with glycine to form hippurate which is excreted by the kidney</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F247200\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics (Adult data unless noted)</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life: 0.75-7.4 hours </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Elimination: Clearance is largely attributable to metabolism with urinary excretion of hippurate, the major metabolite</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F1062163\" class=\"block adi drugH1Div\"><span class=\"drugH1\">Additional Information</span>\n    <p style=\"text-indent:0em;display:inline\">Every 1 mole of benzoate administered removes 1 mole of ammonia as glycine (Kliegman 2016)</p></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Batshaw ML, &ldquo;Hyperammonemia,&rdquo; <i>Curr Probl Pediatr</i>, 1984, 14(11):1-69.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-benzoate-pediatric-drug-information/abstract-text/6510017 /pubmed\" target=\"_blank\" id=\"6510017 \">6510017 </a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Batshaw ML and Brusilow SW, &ldquo;Treatment of Hyperammonemic Coma Caused by Inborn Errors of Urea Synthesis,&rdquo; <i>J Pediatr</i>, 1980, 97(6):893-900.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-benzoate-pediatric-drug-information/abstract-text/7441417/pubmed\" target=\"_blank\" id=\"7441417\">7441417</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Batshaw ML, MacArthur RB, and Tuchman M, &ldquo;Alternative Pathway Therapy for Urea Cycle Disorders: Twenty Years Later,&rdquo; <i>J Pediatr</i>, 2001, 138(1 Suppl):S46-54.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-benzoate-pediatric-drug-information/abstract-text/11148549/pubmed\" target=\"_blank\" id=\"11148549\">11148549</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    H&auml;berle J, Boddaert N, Burlina A, et al. Suggested guidelines for the diagnosis and management of urea cycle disorders. <i>Orphanet J Rare Dis</i>. 2012;7:32.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-benzoate-pediatric-drug-information/abstract-text/22642880/pubmed\" target=\"_blank\" id=\"22642880\">22642880</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Kliegman RM, Stanton BMD, St. Geme J, Schor NF, eds. <i>Nelson Textbook of Pediatrics</i>. 20th ed. Philadelphia, PA: Saunders Elsevier; 2016.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maestri NE, Brusilow SW, Clissold DB, Bassett SS. Long-term treatment of girls with ornithine transcarbamylase deficiency. <i>N Engl J Med</i>. 1996;335(12):855-859.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-benzoate-pediatric-drug-information/abstract-text/8778603/pubmed\" target=\"_blank\" id=\"8778603\">8778603</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Maestri NE, Hauser ER, Bartholomew D, et al, &ldquo;Prospective Treatment of Urea Cycle Disorders,&rdquo; <i>J Pediatr</i>, 1991, 119(6):923-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-benzoate-pediatric-drug-information/abstract-text/1720458/pubmed\" target=\"_blank\" id=\"1720458\">1720458</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Summar M, &ldquo;Current Strategies for the Management of Neonatal Urea Cycle Disorders,&rdquo; <i>J Pediatr</i>, 2001, 138(1 Suppl):S30-9.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/sodium-benzoate-pediatric-drug-information/abstract-text/11148547 /pubmed\" target=\"_blank\" id=\"11148547 \">11148547 </a>]</span></div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 12794 Version 39.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"Therapeutic Category\" href=\"#F1062157\" class=\"outlineLink\">Therapeutic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Neonatal\" href=\"#F11445041\" class=\"outlineLink\">Dosing: Neonatal</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Usual\" href=\"#F1062154\" class=\"outlineLink\">Dosing: Usual</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F247197\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F1062160\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F1062159\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F51130873\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13300050\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F6222963\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F1062156\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F247189\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics (Adult data unless noted)\" href=\"#F247200\" class=\"outlineLink\">Pharmacodynamics/Kinetics (Adult data unless noted)</a></li><li class=\"plainItem\"><a sectionName=\"Additional Information\" href=\"#F1062163\" class=\"outlineLink\">Additional Information</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_PED/12794|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div>","javascript":null}